US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets

US firm ArriVent's shares plummeted after a late-stage trial failure involving a cancer drug licensed from China. This setback highlights the challenges facing Chinese biotech companies as they expand into global markets. The failure of firmonertinib, a cancer treatment originally developed by Shanghai Allist Pharmaceuticals, is a significant blow to ArriVent's stock price, closing down nearly 47 per cent on Tuesday. The outcome underscores the risks associated with biotech companies venturing into international markets, potentially impacting investor confidence in China's biotech sector.

Why it matters

A late-stage trial failure of a cancer drug licensed from China has led to a significant decline in the shares of US firm ArriVent BioPharma. This setback may impact investor confidence in biotech companies, particularly those with ties to China.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to South China Morning Post. For information only — not financial advice.